Clinical Trial Update: An Open-label, Dose-ascending Study of IGT001 for Retinitis Pigmentosa [Phase 1]

View source ↗

Summary

Open-label Phase 1 dose-ascending study evaluating IGT001 for retinitis pigmentosa. The trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinitis Pigmentosa

Drugs mentioned

• IGT001

Snippet

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Conditions: Retinitis Pigmentosa | Phase 1 | Status: RECRUITING